NSE: PARKMEDI CMP: Rs 289.70 P/E: 48.44x ROCE: 19.34% 6M Ret: +97.68% Div Yld: Nil ATH: Rs 297.45
Key Performance Indicators
Park Medi World trades at Rs 289.70 on NSE (PARKMEDI), with a market capitalisation of Rs 12504.28 crore. The price-to-earnings ratio is 48.44x. Return on capital employed stands at 19.34%. The six-month return is +97.68%. Quarterly net profit is Rs 76.77 crore (+58.03% year-on-year change). Quarterly sales stand at Rs 460.41 crore (+30.09% year-on-year). The all-time high is Rs 297.45, 2.7% above the current price.
Highlights
Park Medi World has delivered a six-month return of 97.68%, with a market capitalisation of Rs 12504.28 crore at the current price of Rs 289.70. The all-time high of Rs 297.45 sits 2.7% above the current price, indicating the stock has corrected from its historical peak and offers headroom for appreciation toward that level. The company's ROCE of 19.34% — well above the 15% quality benchmark, placing it among the strongest capital-return businesses in this collection — is a key distinguishing fundamental metric.
The P/E of 48.44x carries a moderate growth premium relative to the Indian market average, pricing in above-economy earnings growth expectations. The healthcare sector tailwinds — rising health insurance penetration, growing chronic disease burden, and government healthcare investment — provide structural support for sustained revenue and earnings growth.
Business Overview
Park Medicare World is a healthcare company providing hospital services, medical devices, or healthcare infrastructure — operating at the intersection of India's growing healthcare demand and the structural expansion of organised hospital networks. India's healthcare sector is expanding with rising health insurance penetration (particularly under Ayushman Bharat), government investment in hospital infrastructure under PM-ABHIM, and growing out-of-pocket healthcare spending from an increasingly health-conscious middle class.
The quarterly profit of Rs 76.77 crore growing 58.03% on revenue of Rs 460.41 crore growing 30.09% year-on-year demonstrates solid profitable growth. The ROCE of 19.34% — approaching the 20% threshold associated with quality compounders — is the standout capital efficiency metric. At Rs 12,504.28 crore market cap with a P/E of 48.44 times, Park Medicare has mid-cap institutional coverage. The six-month return of 97.68% and the all-time high of Rs 297.45 — Rs 7.75 above the current price of Rs 289.70 — indicate the stock is close to its historical ceiling.
Financial Analysis
Park Medi World's most recent quarterly financial results show revenue of Rs 460.41 crore (+30.09% year-on-year) and net profit of Rs 76.77 crore (58.03% year-on-year variation). Profit growth meaningfully exceeding revenue growth indicates improving profitability margins — a positive structural signal if it reflects genuine cost efficiency or product mix improvement rather than temporary factors.
The ROCE of 19.34% is the primary quality indicator for this business. At 19.34%, the company generates exceptional returns on every rupee of capital deployed — a level sustained only by businesses with genuine competitive moats including proprietary technology, strong customer relationships, regulatory barriers to entry, or scale-based cost advantages that prevent competitors from replicating the returns.
At Rs 12504.28 crore — a mid-cap company with growing institutional visibility — Park Medi World is at the scale where institutional investors are beginning to build meaningful positions, creating a potential re-rating catalyst as coverage broadens.
Investor Highlights
The investment case for Park Medi World rests on the combination of a 19.34% ROCE — indicating a capital-efficient business with sustainable competitive advantages — and a demonstrated revenue and earnings growth trajectory that supports the current P/E of 48.44x. High-ROCE businesses are particularly attractive for long-duration compounding: when a company reinvests earnings at 18%+ returns on capital, each rupee retained creates more shareholder value than if it were distributed, making reinvestment in the business mathematically superior to dividend payment at all but very high cost-of-capital environments.
With the current price 2.7% below the all-time high of Rs 297.45, there is established headroom toward the historical peak. If fundamental performance continues to deliver quarterly profit growth and improving ROCE, the stock has a reference target for re-rating toward the all-time high level.
The absence of a dividend yield is consistent with a growth-phase reinvestment strategy — if the ROCE of 19.34% exceeds the shareholder's cost of equity, retaining earnings for reinvestment creates more value than distribution. Investors should assess whether management's capital allocation decisions (capex, acquisitions, working capital) are generating returns consistent with the current ROCE. Investors should access the company's latest annual report and quarterly results on the BSE/NSE portal for current financial data and management commentary on the growth outlook.
Frequently Asked Questions
Q: What does Park Medi World do and why has it delivered a 97.68% six-month return?
A: Park Medi World operates in India's healthcare sector. The 97.68% six-month return reflects a combination of sector-level tailwinds, improving quarterly financial performance — quarterly profit growing 58.03% and revenue growing 30.09% year-on-year — and market re-rating of the company's growth and quality profile. Specific business details and catalysts are documented in BSE/NSE exchange filings.
Q: What does the ROCE of 19.34% indicate about Park Medi World's business quality?
A: Park Medi World's ROCE of 19.34% measures pre-tax profit generated per rupee of total capital employed. At 19.34%, this is an exceptional reading that places the company among India's highest capital-efficiency businesses — indicating strong competitive advantages that protect margins and returns from erosion by competition. Tracking ROCE over multiple quarters provides a leading indicator of business quality improvement or deterioration.
Q: How does the P/E of 48.44x compare to fundamentals for Park Medi World?
A: The P/E of 48.44x should be assessed in conjunction with the earnings growth rate and ROCE. At 48.44x, the stock carries a moderate premium relative to the market average of 20–25x, compensated in part by the ROCE of 19.34% and the quarterly earnings growth of 58.03%.
Q: What is Park Medi World's all-time high and how far is the current price from it?
A: Park Medi World's all-time high is Rs 297.45. The current price of Rs 289.70 is 2.7% below the all-time high, offering potential headroom for appreciation if fundamental performance supports continued market re-rating. The all-time high provides a reference ceiling that informs sentiment and potential price target discussion, though fundamental value — determined by earnings, ROCE, and growth — is the primary determinant of sustainable price levels.
Q: Where can investors access Park Medi World's official financial data and disclosures?
A: Park Medi World's quarterly results, annual reports, investor presentations, shareholding patterns, and all material corporate announcements are filed with NSE and BSE and are freely accessible through the exchange filing portals at nseindia.com and bseindia.com. SEBI listing regulations mandate timely disclosure of all financial results and material developments. These filings are the primary source of verified financial and operational data for investment analysis.